Web Page

This web page provides frequently asked questions for rules on prescribing buprenorphine and other and other medications for opioid use disorder (MOUD), following 2023 policy updates.

This web page provides frequently asked questions regarding the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.

This web page provides frequently asked questions regarding the 2023 Consolidated Appropriations Act, which eliminates the X-waiver (DATA-Waiver) and increases accessibility of medication-assisted treatment (MAT).

This toolkit includes six strategies and checklists for improving one's emotional health, and additional resources about emotional wellness.

The aim of the Lexicon is to describe the functions which define integrated behavioral health in primary care practices to clarify what to implement and what to expect.

This Topic Brief provides an overview of what constitutes low-threshold treatment for patients with OUD, the state of the evidence and patient perspectives on low-threshold OUD treatment, and key steps and strategies for providing low-threshold treatment for patients with OUD in primary care settings.

This Topic Brief provides an overview of the state of the evidence for behavioral health apps and key considerations and concerns related to finding, evaluating, and selecting smartphone and Internet-based behavioral health apps to recommend or prescribe in primary care and integrated care settings.

This Topic Brief covers foundational information on disparities in health and healthcare (including in substance use disorder), the role of behavioral health integration in reducing disparities, and ensuring advancement of health equity within integrated care settings.

This Topic Brief discusses perinatal behavioral health conditions, which include mental health and substance use disorders during pregnancy and the postpartum period (up to 12 months after delivery).

This Topic Brief represents a brief overview of the available research on addressing polysubstance use in a primary care setting with a focus on leveraging an integrated behavioral health team.